By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


RedHill Biopharma Ltd. 

21 Ha’arba’a Street

Tel-Aviv    64739  Israel
Phone: 972-0-3-541-3131 Fax: 972-0-3-541-3144



Company News
RedHill Biopharma Ltd. (RDHL) And IntelGenx Corp. Announce RIZAPORT (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure 9/10/2015 7:39:27 AM
RedHill Biopharma Ltd. (RDHL) Announces $2 Million National Cancer Institute Grant For YELIVA(TM) (ABC294640) Phase II Study For Multiple Myeloma 9/9/2015 7:26:43 AM
RedHill Biopharma Ltd. (RDHL) Announces Standard-Of-Care Eradication Data From The RHB-105 Phase III Study Further Supporting The Study's Positive Results 9/8/2015 8:02:10 AM
RedHill Biopharma Ltd. (RDHL) To Present At The Rodman & Renshaw 17th Annual Global Investment Conference 9/2/2015 8:13:19 AM
RedHill Biopharma Ltd. (RDHL) Announces Last Patient Visit In The Phase I Study With YELIVA (ABC294640) For Advanced Solid Tumors 9/1/2015 7:27:32 AM
Recipharm AB Signs Agreement With RedHill Biopharma Ltd. (RDHL) For Manufacturing Of RHB-105 For Treatment Of H. Pylori Infection 8/26/2015 2:49:02 PM
RedHill Biopharma Ltd. (RDHL) Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease 8/24/2015 9:41:28 AM
RedHill Biopharma Ltd. (RDHL) Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of ABC294640 (YELIVA(TM)) In Prostate Cancer 8/24/2015 7:39:11 AM
RedHill Biopharma Ltd. (RDHL) To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease 8/12/2015 8:06:20 AM
RedHill Biopharma Ltd. (RDHL) Reports Results For The Second Quarter Of 2015 7/29/2015 8:53:04 AM